Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #32 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 19 Sep 2025 | Jusmiral Holdings Limited | Promoter | Sell | 0 | ₹0 |
| 12 May 2025 | Jusmiral Holdings Limited | Promoter | Buy | 0 | ₹0 |
| 12 May 2025 | Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri | Director | Buy | 0 | ₹0 |
| 30 Sep 2023 | JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED | Promoter | Sell | 0 | ₹0 |
| 14 Aug 2023 | PADMAJA J.A.S | Immediate relative | Sell | 0 | ₹0 |
| 17 Feb 2023 | PADMAJA J.A.S | Immediate relative | Sell | 0 | ₹0 |
| 2 Sep 2020 | PADMAJA J.A.S | Immediate relative | Buy | 0 | ₹0 |
| 31 Aug 2020 | PADMAJA J.A.S | Immediate relative | Buy | 0 | ₹0 |
| 27 Aug 2020 | PADMAJA J.A.S | Immediate relative | Buy | 0 | ₹0 |
| 24 Aug 2020 | PADMAJA J.A.S | Immediate relative | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 23 Feb 2026 | JASUB PROPERTY HOLDINGS LLP | Block | Buy | 7,700,000 | 306.0000 | NSE |
| 23 Feb 2026 | JASTI FAMILY TRUST | Block | Sell | 7,700,000 | 306.0000 | NSE |
| 23 Feb 2026 | JASUB PROPERTY HOLDINGS LLP | Bulk | Buy | 7,700,000 | 306.0000 | NSE |
| 23 Feb 2026 | JASTI FAMILY TRUST | Bulk | Sell | 7,700,000 | 306.0000 | NSE |
| 18 Feb 2026 | JASUB PROPERTY HOLDINGS LLP | Block | Buy | 7,000,000 | 309.0000 | NSE |
| 18 Feb 2026 | JASTI FAMILY TRUST | Block | Sell | 7,000,000 | 309.0000 | NSE |
| 18 Feb 2026 | JASUB PROPERTY HOLDINGS LLP | Bulk | Buy | 7,000,000 | 309.0000 | NSE |
| 18 Feb 2026 | JASTI FAMILY TRUST | Bulk | Sell | 7,000,000 | 309.0000 | NSE |
| 23 Oct 2025 | MORGAN STANLEY ASIA (SINGAPORE) PTE. | Block | Sell | 112,492 | 890.7500 | BSE |
| 23 Oct 2025 | BNP PARIBAS FINANCIAL MARKETS | Block | Buy | 112,492 | 890.7500 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 9 Sep 2022 | Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share | 1.0000 | 12 Sep 2022 |
| 13 May 2022 | Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share | 1.0000 | 17 May 2022 |
| 15 Feb 2022 | Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per Share | 1.0000 | 16 Feb 2022 |
| 13 Aug 2021 | Annual General Meeting/Dividend - Re 1 Per Share | 1.0000 | 17 Aug 2021 |
| 17 Feb 2021 | Interim Dividend - Re 1 Per Share | 1.0000 | 18 Feb 2021 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 25 Sep 2020 | BONUS | Bonus 1:1 |
| — | NAME_CHANGE | Name changed from SUVEN PHARMACEUTICALS LIMITED to Cohance Lifesciences Limited |
| 6 Aug 2024 | OTHER | Annual General Meeting |
| 12 Dec 2023 | OTHER | Annual General Meeting |
| 11 Aug 2022 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 5 Aug 2026 | Financial Results | Yes |
| 12 May 2026 | Financial Results | Yes |
| 12 Feb 2026 | Financial Results | Yes |
| 12 Nov 2025 | Financial Results | Yes |
| 13 Aug 2025 | Other business matters | — |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
